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ABSTRACT
Background: Transarterial chemoembolization (TACE) is widely used as a palliative treatment for unresectable 
hepatocellular carcinoma (HCC). TACE is also used as bridging therapy before liver transplantation to avoid 
WXPRXUSURJUHVVLRQDQGFRQVLGHUHGIRUGRZQVWDJLQJWRIXO¿OOWXPRXUUHVHFWLRQRUOLYHUWUDQVSODQWDWLRQFULWHULDV
This study aimed to evaluate response of TACE in unresectable HCC according to changing of tumour size, 
number of lesion, and AFP level.
Method: Retrospectively, we evaluate 69 HCC patients who underwent TACE in Dr. Soetomo General Hospital 
in January 2012-June 2015, including their age, sex, aetiologies, and Barcelona Clinic Liver Cancer/BCLC 
staging. Laboratory examinations such as complete blood count (hemoglobin/Hb, leucocyte, thrombocyte), liver 
function test (aspartate aminotransferase/AST, alanine aminotransferase/ALT, bilirubin, albumin, international 
normalized ratio/INR), alpha-fetoprotein/AFP level, and abdominal CT-scan were performed before and 1 month 
post-TACE. Data was analysed using paired t-test. 
Results: 69 patients with mean age of 51.81 (SD 12.8) years old, predominantly 76.8% males, the most 
common aetiology was hepatitis B (68.1%), BCLC B (92.8%), with stable disease (64.3%), none achieved 
complete response, had tumour size > 5 cm (97.1%), had single tumour (69.6%), and had AFP level >1000 ng/
P/7KHUHZDVDVLJQL¿FDQWLQFUHDVHLQWXPRXUVL]HDQGQXPEHURIOHVLRQVLQPRQWKSRVW7$&(WKDW
ZHUHDSSUR[LPDWHO\FPDQGUHVSHFWLYHO\DQGWKHUHZDVQRVLJQL¿FDQWGLIIHUHQFHEHWZHHQ$)3OHYHO
before and 1 month post TACE. 
Conclusion:,QPRQWKSRVW7$&(HYDOXDWLRQWKHUHZDVQRVLJQL¿FDQWGHFUHDVHRIWXPRXUVL]HDQGQXPEHU
RIOHVLRQDQGDOVRWKHUHZDVQRVLJQL¿FDQWDOWHUDWLRQLQ$)3OHYHO7$&(PLJKWEHSHUIRUPHGUHSHDWHGO\ZLWK
shorter evaluation interval than 1 month to achieve better response. 
Keywords: hepatocellular carcinoma, transarterial chemoembolization, alpha fetoprotein, tumour size, 
number of lesion.
ABSTRAK
Latar belakang: Transarterial chemoembolization (TACE) telah digunakan secara luas sebagai pengobatan 
paliatif untuk karsinoma hepatoselular yang telah dioperasi. TACE juga digunakan sebagai terapi awal sebelum 
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transplantasi hati untuk menghindari perkembangan tumor dan dianggap sebagai fase awal untuk memenuhi 
reseksi tumor atau memenuhi kriteria transplantasi hati. Penelitian ini bertujuan untuk mengevaluasi respon 
TACE  pada karsinoma hepatoselular yang telah dioperasi terkait perubahan ukuran tumor, jumlah lesi, dan 
level alpha-fetoprotein. 
Metode: Secara retrospektif, penelitian ini mengevaluasi 69 pasien karsinoma hepatoselular yang menjalani 
TACE di Rumah Sakit Umum Dr. Soetomo pada Januari 2012-Juni 2015, termasuk umur, jenis kelamin, etiologi, 
dan stase Barcelona Clinic Liver Cancer (BCLC). Pemeriksaan laboratorium seperti perhitungan darah lengkap 
(hemoglobin/Hb, leukosit, trombosit), tes fungsi hati (aspartate aminotransferase/AST, alanine aminotransferase/
ALT, bilirubin, albumin, international normalized ratio/INR), level alpha-fetoprotein, dan CT-scan abdominal 
dilakukan 1 bulan sebelum dan setelah TACE. Data dianalisis menggunakan uji t berpasangan.
Hasil: Sebanyak 69 pasien dengan rerata umur 51.81 ± 12.8 tahun, dominan pada laki-laki sebesar 76.8%, 
etiologi yang paling sering adalah hepatitis B sebesar 68.1%, 92.8% merupakan BCLC B, 64.3% merupakan 
penyakit yang stabil, tidak satupun menerima respon lengkap, 97.1% memiliki ukuran tumor > 5 cm, 69.6% 
PHPLOLNL WXPRU WXQJJDOGDQPHPLOLNL NDGDU$)3!QJP/$GDSHQDPEDKDQ VLJQL¿NDQSDGD
ukuran tumor dan jumlah lesi pada satu bulan setelah TACE secara berturut-turut 1.76 dan 2.33 cm, dan tidak 
DGDSHUEHGDDQVLJQL¿NDQDQWDUDNDGDU$)3VDWXEXODQVHEHOXPGDQVHWHODK7$&(
Simpulan: 'DODPVDWXEXODQVHWHODKHYDOXDVL7$&(DGDSHQDPEDKDQVLJQL¿NDQXNXUDQWXPRUGDQMXPODK
OHVLQDPXQWLGDNDGDSHUXEDKDQVLJQL¿NDQSDGDNDGDU$)37$&(PXQJNLQGLODNXNDQVHFDUDEHUXODQJGHQJDQ
jarak evaluasi yang lebih singkat dari 1 bulan untuk mendapatkan respon yang lebih baik.
.DWDNXQFL karsinoma hepatoselular, transarterial chemoembolization (TACE), alpha-fetoprotein, ukuran 
tumor, jumlah lesi.
INTRODUCTION
+HSDWRFHOOXODUFDUFLQRPD+&&LVWKH¿IWKOHDGLQJ
cause of cancer and third leading cause of death among 
cancer worldwide, with incidence about 14.7% and 4.9% 
per 100.000 patients, respectively.1,2 Approximately 
70-90% HCC patients suffered from chronic liver 
disease or cirrhosis manifestations prior to HCC, with 
hepatitis B infection, hepatitis C infection, non-alcoholic 
and alcoholic fatty liver disease as the main causes.2,3 
Treatment of choice in HCC depends on tumour size, 
number of lesions, patient’s performance status, and 
liver functional reserve, that were presented in BCLC 
staging.4,5 During initial diagnosis, only 30% patients 
IXO¿OOHGWKHFULWHULDIRUFXUDWLYHWUHDWPHQWVXFKDVOLYHU
transplant, ablation therapy, and surgical resection, 
whereas others were not suitable for curative therapy 
so they had to underwent palliative treatment, such as 
transarterial chemoembolization (TACE) and Sorafenib.1,6
TACE is treatment strategy that is recommended 
for HCC patients with intermediate stage, where 
there is large uninodular and multinodular HCC with 
preserved liver function (Child A/B), and without 
vascular invasion or extrahepatic dissemination.5,7 
Rationalization of TACE in HCC is based on 2 
vascularization. First, portal vein that gives nutrition 
to liver parenchyma, and second, hepatic artery that 
gives nutrition to the tumour with various stage of 
hypervascularization. Administration of transarterial 
cytotoxic drugs combined with arterial embolization 
will cause local cytotoxic effect and tumour ischemia.1,8 
Response to TACE could be evaluated through 
the decreasing of tumour marker level, amount of 
intratumour necrotic area, and shrinking of tumour 
size and number of tumour lesions. These responses 
were associated with better survival.5,9
Although TACE has direct anti tumour effect, it 
can also cause complications such as increasing of 
transaminase serum level and negative changes in liver 
function, that probably caused by ischemic injury in liver 
and also tumour necrosis.10,11,12 Alpha-fetoprotein (AFP) 
is protein from fetal component that is produced by fetal 
liver and gestasional sac during embryo period. Adult AFP 
normal level is < 20 ng/mL. High AFP serum level was 
found in 60-70% HCC patients, but was still normal in 
15-30% patients. False positive results are usually found 
in many conditions such as pregnancy, liver cirrhosis, lung 
cancer, biliary cancer, gastric cancer, pancreatic cancer, 
testicular cancer, and drugs/alcohol abuse.5,13-18 In this 
VWXG\ZHHYDOXDWHG WKH LQÀXHQFHRI7$&(WR WXPRXU
size, number of lesions, and AFP serum levels. 
METHOD
We compiled secondary data from medical 
records in interventional radiology department and 
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gastrohepatology outpatient clinic in Dr. Soetomo 
General Hospital, including all patients above 18 
years old, who were diagnosed with HCC stage BCLC 
%&DQGXQGHUZHQW¿UVW7$&(GXULQJ-DQXDU\
to June 2015 period. Diagnosis of HCC was based 
on European Association for The Study of The Liver 
(EASL) criteria, where there was classical lesion in 2 
radiology imaging (CT-Scan/MRI/USG) or 1 radiology 
imaging, with elevation of AFP serum level > 400 
QJP/RUKLVWRSDWKRORJ\¿QGLQJVKRZLQJ+&&IURP
liver biopsy. Exclusion criteria were: (1) Presence of 
liver decompensation signs and symptoms (ascites, 
active gastrointestinal bleeding, encephalopathy, 
liver failure); (2) Had been underwent resection 
therapy, ablation, transplant, or TACE; (3) Presence 
of severe illness Karnoffsky score < 50); (4) Presence 
of history of malignancy before HCC or HCC that 
has metastasized; (5) Presence of history of coronary 
heart disease, heart failure, or chronic renal failure. We 
IRXQGSDWLHQWVZKRIXO¿OOHGLQFOXVLRQDQGH[FOXVLRQ
criteria.
Data that were collected include age, sex, 
HCC aetiologies (hepatitis B and hepatitis C viral 
marker), BCLC staging, and chief complaint. Data 
of hemoglobin, leucocyte, trombocyte, AST, ALT, 
bilirubin, albumin, AFP, tumour size, and number of 
lesions that were collected were initial data (before 
¿UVWVHVVLRQRI7$&(DQGGDWDPRQWKDIWHUWKH¿UVW
session of TACE session, when patients came to the 
gastro-hepatology outpatient clinic. CT scan abdomen 
IRUHYDOXDWLRQZDVSHUIRUPHGPRQWKDIWHUWKH¿UVW
VHVVLRQRI7$&(7XPRXUVL]HZDVGH¿QHGDVODUJHVW
tumour diameter and if there was multiple tumour, 
WXPRXU VL]HZDV GH¿QHG DV VXPRI ODUJHVW WXPRXU
diameter from all lesions. 
TACE procedure was performed according to 
the standardised protocol and was performed by 
experienced interventionist in interventional radiology 
unit in Dr. Soetomo General Hospital Surabaya. 
TACE was performed percutaneously using Seldinger 
technique. After catheter 5 Fr was inserted into femoral 
DUWHU\DQJLRJUDSK\ZDVGRQHWRHYDOXDWHEORRGÀRZ
of left and right hepatica arteries. After that, selective 
catheterization was performed to arteries that gave 
blood supply to the tumour. TACE was performed 
with combination suspension of chemotherapy drugs, 
that consisted of Doxorubicin 10-40 mg with or 
without carboplatin 450 mg mixed in 10 mL lipiodol, 
followed by embolization using gel foam. The 
procedure was complete if from contrast test result, 
WKHUHZDV QR DUWHULDO EORRGÀRZ OHIW WR WKH WXPRXU
(devascularization). Amount of chemotherapy drugs 
and lipiodol was given according to the number, 
location, and diameter of lesions. 
Data were collected and analyzed using SPSS 
software version 20. Qualitative data was presented 
in number and percentage. Quantitative data was 
presented in mean and standard deviation (X r SD). 
Comparison quantitative data before and 1 month after 
¿UVWVHVVLRQRI7$&(ZHUHDQDO\VHGXVLQJSDLUHGWWHVW
3YDOXHRIZDVFRQVLGHUHGDVVLJQL¿FDQW
RESULTS
7KHUHZHUHSDWLHQWVZKRIXO¿OOHGLQFOXVLRQDQG
exclusion criterias in this study, consisting of 53 male 
patients (76.8%) and 16 female patients (23.2%), with 
mean age of 51.81 (SD 12.8) years old; with aetiology 
of HCC: hepatitis B in 47 patients (68.1%), hepatitis 
C in 9 patients (13%), and other causes (other than 
hepatitis B and C infection) in 13 patients (18.8%); 
2 patients (2.9%) with HCC BCLC A, 64 patients 
(92.8%) with BCLC B, and 3 patients (4.3%) with 
BCLC C; 14 patients (22.9%) with AFP level < 200 
ng/mL, 13 patients (21.3%) with AFP level 200-1000 
ng/mL, and 34 patients (55.7%) with AFP level > 1000 
ng/mL. During initial diagnosis, 67 patients (97.1%) 
had tumour size of > 5 cm, and 2 patients (2.9%) had 
tumour size of 2-5 cm, with mean of 12.14 (SD 4.3 cm); 
48 patients (69.6%) had solitary tumour and 21 patients 
(30.4%) had multiple tumour, with mean number of 
lesions 1.33 (SD 0.56) Patients’ characteristic were 
presented in Table 1.
)URPODERUDWRU\¿QGLQJVZHIRXQGPHDQDOEXPLQ
level (pre-TACE) of 3.25 (SD 0.41) g/dL and 1 month 
post TACE 3.26 (SD 0.41)g/dL; total bilirubin level 
(pre-TACE) 1.44 (SD 0.56) mg/dL and 1 month post-
TACE 1.78 (SD 2.54) mg/dL; AST (pre-TACE) 136.41 
(SD 117.84) U/L and 1 month post-TACE 136.03 
(SD 121.53) U/L; ALT (pre-TACE) 74.19 (SD 76.14) 
U/L and 1 month post-TACE 63.36 (SD 41.26) U/L; 
hemoglobin (pre-TACE) 12.94 (SD 1.86) g/L and 1 
month post-TACE 12.72 (SD 1.66) g/L; leucocyte 
(pre-TACE) 6804.77 (SD 2661.9)/uL and 1 month 
post-TACE 6296.65 (SD 2210.93)/uL; thrombocyte 
(pre-TACE) 195258.41 (SD 99525.02)/uL and 1 month 
post-TACE 178363.77 (SD 90445.63)/uL. Data was 
shown in Table 2. 
In this study, evaluation of TACE included tumour 
size, number of tumour lesions, and AFP level before 
and 1 month post TACE. Statistical analysis showed 
VLJQL¿FDQWFRUUHODWLRQEHWZHHQWXPRXUVL]HQXPEHURI
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tumour lesions, and AFP level before and 1 month post 
7$&(S7KHUHZDVDVLJQL¿FDQWLQFUHDVHRI
tumour size in 1 month post-TACE (p = 0.008) with 
mean tumour size pre-TACE of 12.17 r 4.43 cm and 
1 month post-TACE of 13.94 r 5.94 cm, with mean 
LQFUHDVH RI  FP7KHUHZDV DOVR D VLJQL¿FDQW
LQFUHDVHRIQXPEHURIOHVLRQVVLJQL¿FDQWO\LQPRQWK
post-TACE (p = 0.012) with mean number of lesions 
pre-TACE 1.35 r 0.58 and 1 month post-TACE 
1.58 r 0.72, with mean increase of 2.33. Number of 
patients with AFP level >1000 ng/mL pre-TACE was 
38 patients and decreased to 29 patients in 1 month 
post-TACE, patients with AFP level 200-1000 ng/mL 
pre-TACE was 13 patients and increased to 24 patients 
in 1 month post-TACE, and patients with AFP level 
< 200 ng/mL was 13 patients decreased to 12 patients. 
However, these fluctuations were not significant 
(p > 0.05). Graph was shown in Figure 1.
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Figure 1. TACE effect to tumour size and number of tumour 
lesions
Table 1. Demographic and tumour characteristics of patients 
who underwent transarterial chemoembolization (TACE)
Variables (n = 69) n (%) mean (SD)
Demography
Age (year old)
Gender
Male
Female
Liver function
ALT (IU/L)

!
AST (IU/L)

!
Albumin
< 3
3-3.5
> 3.5
Bilirubin total (mg/dL)
< 2
2-2.5
Aetiologies
Hepatitis B 
Hepatitis C
Others
Tumour marker
AFP (ng/mL)


!
Tumour characteristic
Tumour size (cm)
2-5
> 5
Number of lesions
Solitaire
Multiple
Staging BCLC
BCLC A
BCLC B
BCLC C
Main Complaints
Abdominal pain
Weight loss
Abdominal lump
Abdominal discomfort/ 
        nausea/vomit
Others (icterus/
haematemesis-melena/ 
Oedema, etc)
Chemotherapy Drug
Doxorubicin
Doxorubicin-Carboplatin
53/76.8



5/7.2





















25/36.2


36/52.2







ALT: alanine aminotransferase, AST: aspartate aminotransferase, 
AFP: alpha-fetoprotein: BCLC: Barcelona clinic liver cancer
7DEOH/DERUDWRU\¿QGLQJVSUH7$&(DQGPRQWKSRVW7$&(
Variables Pre-TACE  mean (SD)
1 month post TACE
mean (SD)
AST  
ALT  
Hemoglobin  
Leucocyte  
Thrombocyte  
INR  
Albumin  
Total Bilirubin  
AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
INR: International normalized ratio; TACE: transarterial chemoembolization
 DISCUSSION
+HSDWRFHOOXODUFDUFLQRPD+&&LVWKH¿IWKOHDGLQJ
cancer and third leading cause of death among cancer, 
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worldwide, with high mortality rates.1,2 TACE is the 
main palliative treatment of choice for HCC patients 
ZKRGLGQRWIXO¿OFULWHULDIRUVXUJHU\5,7 In one meta-
analysis that included 18 randomised-controlled 
clinical trial, Camma et al, showed better survival in 
TACE group compared to the control group.19
Chronic hepatitis B and hepatitis C infection are 
major risk factors of HCC, besides other causes, such as 
metabolic syndrome (obesity, diabetes mellitus), alcohol, 
toxin, drugs, and autoimmune.20 In this study, the most 
common risk factor of HCC was hepatitis B infection. 
This was consistent with prior studies, where hepatitis 
B-associated HCC was mostly found in Asian, Africa, and 
Latin America Countries, whereas hepatitis C-associated 
HCC was mostly found in countries in Europe, North 
America, Japan, Mongolian, and Egypt.21,22,23,24
Male had higher risk for HCC, with ratio to female 
about 2-4:1. In this study, male HCC patients were 
more than female with ratio of about 3:1. Genetic 
susceptibility factors and hormonal factors, as well as 
smoking and alcohol drinking habits were believed as 
strong risk factors for HCC in male.15,20,25-30 
Elevation of AFP level could reflect abnormal 
hepatocyte regeneration, so AFP was long used as 
marker to detect HCC. High AFP serum level was 
found in 60-70% HCC patients, but was still at normal 
level in 15-30% patients.5,13 For diagnosis, AFP level 
QJP/VKRZHGKLJKVHQVLWLYLW\DQGORZVSHFL¿FLW\
but in level 200 ng/mL, its sensitivity decreased to only 
ZLWKKLJKVSHFL¿FLW\31,32 In this study, we found 
14 patients (22.9%) with AFP level < 200 ng/mL, 13 
patients (21.3%) with AFP level 200-1000 ng/mL, and 
34 patients (55.7%) with AFP level >1000 ng/mL. We 
used upper cut-off of 1000 because AFP level data in 
this study could not detect absolute amount higher 
than 1000 ng/mL. Survival is the main goal of TACE 
in HCC, but evaluation of tumour local response is 
also important to evaluate the effectiveness of TACE 
technique. Tumour local response evaluation with CT-
Scan or MRI could be done in 1-3 months after TACE 
procedure.1 In this study, we did not evaluate survival, 
but only tumour local response that we observed from 
tumour size, number of tumour lesions, and tumour 
marker level in 1 month post TACE.33,34,35 Tumour 
ORFDOUHVSRQVHZDVDOVRLQÀXHQFHGE\GLIIHUHQW7$&(
technique or chemotherapy drugs and embolization, 
but were not evaluated in this study.1 
Large tumour size is a risk factor for tumour 
recurrence, although in this study, it was found that 
early tumour reccurency could also happen in small 
tumour, in resectable HCC.36 In this study, there was 
DVLJQL¿FDQW LQFUHDVHRI WXPRXUVL]HDQGQXPEHURI
tumour lesion in 1 month post TACE, with mean of 
about 1.76 cm and 2.33, respectively. These results 
were consistent with prior studies, where it was so 
rare to achieve complete response after TACE (0-4%), 
even tumour often adapted to the new angiogenesis. 
Therefore, in the next evaluation, usually increased size 
or number of tumour lesions was found.35 In contrast, 
RWKHUVWXG\IRXQGVLJQL¿FDQWGHFUHDVHRIWXPRXUVL]H
and number of tumour lesions post TACE, but in this 
study, evaluation was performed 1 week post TACE, 
where neoangiogenesis process had not increase 
WXPRXUVL]HRUQXPEHURIWXPRXUOHVLRQVVLJQL¿FDQWO\
compared to evaluation in 1 month post TACE.37
Decrease of > 50% AFP level from initial level 
after locoregional therapy such as TACE and 
radioembolization, was reported to be useful in evaluate 
tumour response and survival, also in evaluating 
progressivity of lesion that could be seen through 
radiology examination.18,33 AFP level also had been 
studied as prognostic predictor of resectable HCC.2,17 
In this study, patients with AFP level >1000 ng/mL.
In this study, patients whose AFP level were > 
1000 ng/mL pre-TACE were 34 patients, and this 
number decreased to 24 patients in 1 month post-
TACE. Patients whose AFP level were 200-1000 ng/
mL pre-TACE were 13 and this increased to 24 patients 
in 1 month post-TACE, while 13 patients with AFP 
level < 200 ng/mL decreased to 12 patients in 1 month 
SRVW7$&(+RZHYHU WKHVHÀXFWXDWLRQV LQ SDWLHQWV
QXPEHUZHUH QRW VLJQL¿FDQWO\ GLIIHUHQW7KLV VWXG\
FRXOGQRWUHÀHFWDOOSRSXODWLRQEHFDXVHRQO\SHUIRUPHG
in one health center, with small sample size, short 
follow-up time (only 1 month) so it could not asses 
survival. The future studies with longer time of follow 
up, bigger sample size, and evaluation of survival are 
needed to achieve better results which can be applied 
in bigger population, especially in Indonesia. 
CONCLUSION
From this study, it could be concluded that tumour 
VL]HDQGQXPEHURIWXPRXUOHVLRQZHUHVLJQL¿FDQWO\
increased in 1 month post TACE, whereas AFP level 
EHIRUHDQGPRQWKSRVW7$&(ZHUHQRWVLJQL¿FDQWO\
different. Therefore, the decision to perform TACE as 
FKRLFHRI+&&WUHDWPHQWZDVLQGLYLGXDODQGEHQH¿W
to-risk ratio must be considered. 
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